BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Noori-daloii MR, Saffari M, Raoofian R, Yekaninejad M, Dinehkabodi OS, Noori-daloii AR. The multidrug resistance pumps are inhibited by silibinin and apoptosis induced in K562 and KCL22 leukemia cell lines. Leukemia Research 2014;38:575-80. [DOI: 10.1016/j.leukres.2013.10.028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Tilekar K, Upadhyay N, Iancu CV, Pokrovsky V, Choe JY, Ramaa CS. Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer. Biochim Biophys Acta Rev Cancer. 2020;1874:188457. [PMID: 33096154 DOI: 10.1016/j.bbcan.2020.188457] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
2 Zhang J, Li X, Huang L. Anticancer activities of phytoconstituents and their liposomal targeting strategies against tumor cells and the microenvironment. Adv Drug Deliv Rev 2020;154-155:245-73. [PMID: 32473991 DOI: 10.1016/j.addr.2020.05.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
3 Delmas D, Xiao J, Vejux A, Aires V. Silymarin and Cancer: A Dual Strategy in Both in Chemoprevention and Chemosensitivity. Molecules 2020;25:E2009. [PMID: 32344919 DOI: 10.3390/molecules25092009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 18.0] [Reference Citation Analysis]
4 Afonso J, Santos LL, Longatto-Filho A, Baltazar F. Competitive glucose metabolism as a target to boost bladder cancer immunotherapy. Nat Rev Urol 2020;17:77-106. [PMID: 31953517 DOI: 10.1038/s41585-019-0263-6] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 27.0] [Reference Citation Analysis]
5 Elshimali YI, Wu Y, Khaddour H, Wu Y, Gradinaru D, Sukhija H, Chung SS, Vadgama JV. Optimization Of Cancer Treatment Through Overcoming Drug Resistance. J Cancer Res Oncobiol 2018;1:107. [PMID: 29932172 DOI: 10.31021/jcro.20181107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
6 Kochel TJ, Reader JC, Ma X, Kundu N, Fulton AM. Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer. Oncotarget 2017;8:6540-54. [PMID: 28029661 DOI: 10.18632/oncotarget.14145] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 9.5] [Reference Citation Analysis]
7 Sak K, Everaus H. Established Human Cell Lines as Models to Study Anti-leukemic Effects of Flavonoids. Curr Genomics 2017;18:3-26. [PMID: 28503087 DOI: 10.2174/1389202917666160803165447] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
8 Carrasco-torres G, Fattel-fazenda S, López-alvarez GS, García-román R, Villa-treviño S, Vásquez-garzón VR. The transmembrane transporter ABCC3 participates in liver cancer progression and is a potential biomarker. Tumor Biol 2016;37:2007-14. [DOI: 10.1007/s13277-015-3999-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
9 Dharmapuri G, Doneti R, Philip GH, Kalle AM. Celecoxib sensitizes imatinib-resistant K562 cells to imatinib by inhibiting MRP1-5, ABCA2 and ABCG2 transporters via Wnt and Ras signaling pathways. Leuk Res. 2015;39:696-701. [PMID: 25916699 DOI: 10.1016/j.leukres.2015.02.013] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]